Exhibit 99.1 Ironwood Pharmaceuticals Reports First Quarter 2024 Results – Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II exploratory STARGAZE trial of apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus- Host Disease (SR GI aGVHD) – – LINZESS (Iinaclotide) EUTRx prescription demand growth of 10% year-over-year – – Re ...